AbSci (ABSI) Stock Forecast & Price Target

Compare

1,181 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ABSI Analyst Ratings

Strong Buy

7 Buy

0 Hold

0 Sell

Based on 7 analysts giving stock ratings to

AbSci

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ABSI Stock 12 Month Forecast

Average Price Target

$8.25

▲(114.84% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for AbSci in the last 3 months. The average price target is $8.25 with a high forecast of $10.00 and a low forecast of $7.00. The average price target represents a 114.84% change from the last price of $3.84.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","6":"$6","11":"$11","3.5":"$3.5","8.5":"$8.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,3.5,6,8.5,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.04,3.5753846153846154,4.110769230769231,4.646153846153846,5.181538461538461,5.716923076923077,6.252307692307692,6.787692307692307,7.323076923076923,7.858461538461538,8.393846153846154,8.92923076923077,9.464615384615385,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.04,3.440769230769231,3.8415384615384616,4.242307692307692,4.643076923076923,5.043846153846154,5.444615384615385,5.845384615384615,6.246153846153846,6.646923076923077,7.047692307692308,7.4484615384615385,7.849230769230769,{"y":8.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.04,3.3446153846153845,3.649230769230769,3.953846153846154,4.258461538461539,4.563076923076923,4.867692307692308,5.172307692307692,5.476923076923077,5.781538461538462,6.086153846153846,6.390769230769231,6.695384615384615,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.92,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.15,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.62,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.85,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.4,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.03,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.73,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.59,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.34,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.13,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.28,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.04,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$10.00

Average Price Target$8.25

Lowest Price Target$7.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

12/12/25

Analysts Offer Insights on Healthcare Companies: Genmab (NASDAQ: GMAB), Evolent Health (NYSE: EVH) and AbSci (NASDAQ: ABSI)

Gil Blum

Needham

Buy

82.29%

Upside

Reiterated

12/12/25

Promising Prospects for AbSci's ABS-201 in Androgenetic Alopecia: Buy Rating Affirmed

Debanjana Chatterjee

JonesTrading

Buy

134.38%

Upside

Reiterated

12/04/25

Promising Developments in AbSci's ABS-201 Program and Market Potential

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

$10

Buy

160.42%

Upside

Reiterated

11/17/25

AbSci (ABSI) Gets a Buy from Guggenheim

Swayampakula Ramakanth

H.C. Wainwright

Buy

82.29%

Upside

Reiterated

11/14/25

Strategic Developments and Promising Prospects Drive Buy Rating for AbSci

Brendan Smith

TD Cowen

―

Buy

―

Reiterated

11/12/25

Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (NASDAQ: ELVN) and AbSci (NASDAQ: ABSI)We continue to believe that progressing with an SC formulation will be critical to maximizing the long-term commercial opportunity. Updated preclinical data and additional information on both ABS-201 studies will be released during the company's R&D day and KOL seminar on December 11, 2025.

Brian Cheng

J.P. Morgan

―

Buy

―

Initiated

10/02/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Sean Laaman

Morgan Stanley

$6.4→$5.89

Buy

53.39%

Upside

Reiterated

08/18/25

AbSci (ABSI) Gets a Buy from Morgan StanleyABSI.O ABSCI CORP Overweight with price target change from 6.40 to 5.89.

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

$10

Buy

160.42%

Upside

Reiterated

05/14/25

We remain Buy rated with a $10 price target.

George Farmer

Scotiabank

$13

Buy

238.54%

Upside

Reiterated

05/14/25

Scotiabank Keeps Their Buy Rating on AbSci (ABSI)

Scott Schoenhaus

KeyBanc

$5→$9

Buy

134.38%

Upside

Reiterated

04/16/25

KeyBanc Reaffirms Their Buy Rating on AbSci (ABSI)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

12/12/25

Analysts Offer Insights on Healthcare Companies: Genmab (NASDAQ: GMAB), Evolent Health (NYSE: EVH) and AbSci (NASDAQ: ABSI)

Gil Blum

Needham

Buy

82.29%

Upside

Reiterated

12/12/25

Promising Prospects for AbSci's ABS-201 in Androgenetic Alopecia: Buy Rating Affirmed

Debanjana Chatterjee

JonesTrading

Buy

134.38%

Upside

Reiterated

12/04/25

Promising Developments in AbSci's ABS-201 Program and Market Potential

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

$10

Buy

160.42%

Upside

Reiterated

11/17/25

AbSci (ABSI) Gets a Buy from Guggenheim

Swayampakula Ramakanth

H.C. Wainwright

Buy

82.29%

Upside

Reiterated

11/14/25

Strategic Developments and Promising Prospects Drive Buy Rating for AbSci

Brendan Smith

TD Cowen

―

Buy

―

Reiterated

11/12/25

Brian Cheng

J.P. Morgan

―

Buy

―

Initiated

10/02/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Sean Laaman

Morgan Stanley

$6.4→$5.89

Buy

53.39%

Upside

Reiterated

08/18/25

AbSci (ABSI) Gets a Buy from Morgan StanleyABSI.O ABSCI CORP Overweight with price target change from 6.40 to 5.89.

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

$10

Buy

160.42%

Upside

Reiterated

05/14/25

We remain Buy rated with a $10 price target.

George Farmer

Scotiabank

$13

Buy

238.54%

Upside

Reiterated

05/14/25

Scotiabank Keeps Their Buy Rating on AbSci (ABSI)

Scott Schoenhaus

KeyBanc

$5→$9

Buy

134.38%

Upside

Reiterated

04/16/25

KeyBanc Reaffirms Their Buy Rating on AbSci (ABSI)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AbSci

1 Month

xxx

Success Rate

5/7 ratings generated profit

Average Return

+4.76%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 71.43% of your transactions generating a profit, with an average return of +4.76% per trade.

3 Months

xxx

Success Rate

6/7 ratings generated profit

Average Return

+6.56%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 85.71% of your transactions generating a profit, with an average return of +6.56% per trade.

1 Year

Debanjana ChatterjeeJonesTrading

Success Rate

7/7 ratings generated profit

Average Return

+25.97%

reiterated a buy rating 10 days ago

Copying Debanjana Chatterjee's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +25.97% per trade.

2 Years

xxx

Success Rate

7/7 ratings generated profit

Average Return

+27.07%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +27.07% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ABSI Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ABSI has received 12 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. ABSI average Analyst price target in the past 3 months is 8.25.

Each month's total comprises the sum of three months' worth of ratings.

ABSI Financial Forecast

ABSI Earnings Forecast

Next quarter’s earnings estimate for ABSI is -$0.18 with a range of -$0.22 to -$0.11. The previous quarter’s EPS was -$0.20. ABSI beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year ABSI has Performed in-line its overall industry.

ABSI Sales Forecast

Next quarter’s sales forecast for ABSI is $1.42M with a range of $0.00 to $3.35M. The previous quarter’s sales results were $378.00K. ABSI beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year ABSI has Performed in-line its overall industry.

ABSI Stock Forecast FAQ

What is ABSI’s average 12-month price target, according to analysts?

Based on analyst ratings, AbSci’s 12-month average price target is 8.25.

What is ABSI’s upside potential, based on the analysts’ average price target?

AbSci has 114.84% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ABSI a Buy, Sell or Hold?

AbSci has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.

What is AbSci’s price target?

The average price target for AbSci is 8.25. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $10.00 ,the lowest forecast is $7.00. The average price target represents 114.84% Increase from the current price of $3.84.

What do analysts say about AbSci?

AbSci’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of ABSI?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

AbSci (ABSI) Stock Forecast & Price Target

ABSI Analyst Ratings

ABSI Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering AbSci

ABSI Analyst Recommendation Trends

ABSI Financial Forecast

ABSI Earnings Forecast

ABSI Sales Forecast

ABSI Stock Forecast FAQ

Detailed List of Analyst Forecasts